CTLA4 and oropharynx cancer: ICIs immunotherapy consisting of anti-CTLA4 and anti-PD1 has been shown to be effective in non-small cell lung cancers and oropharyngeal cancer, and the feasibility of applying immunotherapy to cervical cancer is receiving increasing attention and research51,52.